ANI PHARMACEUTICALS, INC (ANIP) Operating Margin
- Operating margin · 12 months: Value 15.37%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 15.37% | Operating income / revenue. Period ending 2026-06-30. $150.35M ÷ $978.38M × 100 ≈ 15.37% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 150.35M USD | Operating Income (Loss) |
| Revenue | 978.38M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 49.91M USD | Research and Development Expense |
| Selling, general and administration | 324.76M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $150.35M | $978.38M | (m) | $49.91M | $324.76M | 15.37% |
| 2026-03-31 | $123.79M | $923.71M | (m) | $51.70M | $314.87M | 13.40% |
| 2025-12-31 | $111.09M | $883.37M | (m) | $51.66M | $317.75M | 12.58% |
| 2025-09-30 | $71.95M | $826.88M | (m) | $56.05M | $304.67M | 8.70% |
| 2025-06-30 | $15.19M | $747.40M | (m) | $53.87M | $307.09M | 2.03% |
| 2025-03-31 | $6.47M | $674.07M | (m) | $44.63M | $278.14M | 0.96% |
| 2024-12-31 | $584.00K | $614.38M | (m) | $44.58M | $249.64M | 0.10% |
| 2024-09-30 | $11.69M | $555.46M | (m) | $37.80M | $224.38M | 2.10% |
| 2024-06-30 | $50.16M | $538.95M | (m) | $38.80M | $187.31M | 9.31% |
| 2024-03-31 | $57.39M | $517.46M | (m) | $38.87M | $173.25M | 11.09% |
| 2023-12-31 | $46.97M | $486.82M | (m) | $34.29M | $161.70M | 9.65% |
| 2023-09-30 | $42.06M | $449.39M | (m) | $29.64M | $150.42M | 9.36% |
| 2023-06-30 | $19.12M | $401.39M | (m) | $26.18M | $138.50M | 4.76% |
| 2023-03-31 | $-6.19M | $358.69M | (m) | $22.97M | $131.69M | -1.73% |
| 2022-12-31 | $-35.28M | $316.38M | (m) | $22.32M | $124.04M | -11.15% |
| 2022-09-30 | $-60.83M | $283.08M | (m) | $20.24M | $121.56M | -21.49% |
| 2022-06-30 | $-59.39M | $251.32M | (m) | $15.04M | $108.66M | -23.63% |
| 2022-03-31 | $-62.03M | $226.09M | (m) | $13.68M | $95.52M | -27.44% |
| 2021-12-31 | $-39.79M | $216.14M | (m) | $11.37M | $84.29M | -18.41% |
| 2021-09-30 | $-15.74M | $212.46M | (m) | $11.91M | $67.95M | -7.41% |
| 2021-06-30 | $-9.38M | $213.38M | (m) | $12.39M | $66.50M | -4.39% |
| 2021-03-31 | $-5.13M | $213.22M | (m) | $12.63M | $68.89M | -2.41% |
| 2020-12-31 | $-16.02M | $208.47M | (m) | $16.00M | $64.99M | -7.68% |
| 2020-09-30 | $-21.02M | $199.19M | (m) | $17.00M | $64.64M | -10.55% |
| 2020-06-30 | $-16.49M | $197.55M | (m) | $19.04M | $63.27M | -8.35% |
| 2020-03-31 | $4.11M | $203.43M | (m) | $21.78M | $56.24M | 2.02% |
| 2019-12-31 | $16.35M | $206.55M | (m) | $19.81M | $55.84M | 7.92% |
| 2019-09-30 | $32.47M | $215.70M | (m) | $18.61M | $55.20M | 15.05% |
| 2019-06-30 | $35.25M | $215.07M | (m) | $18.30M | $52.62M | 16.39% |
| 2019-03-31 | $33.22M | $207.98M | (m) | $17.66M | $48.39M | 15.97% |
| 2018-12-31 | $35.36M | $201.58M | (m) | $15.39M | $44.06M | 17.54% |
| 2018-09-30 | $31.29M | $191.74M | (m) | $14.56M | $39.57M | 16.32% |
| 2018-06-30 | $30.51M | $189.20M | (m) | $12.52M | $35.83M | 16.13% |
| 2018-03-31 | $30.24M | $186.70M | (m) | $9.55M | $33.24M | 16.20% |
| 2017-12-31 | $28.33M | $176.84M | (m) | $9.07M | $31.58M | 16.02% |
| 2017-09-30 | $22.25M | $167.76M | (m) | $6.55M | $30.06M | 13.26% |
| 2017-06-30 | $20.84M | $158.12M | (m) | $4.96M | $28.97M | 13.18% |
| 2017-03-31 | $19.04M | $144.69M | (m) | $3.56M | $29.22M | 13.16% |
| 2016-12-31 | $20.08M | $128.62M | (m) | $2.91M | $27.83M | 15.61% |
| 2016-09-30 | $25.05M | $108.45M | (m) | $3.43M | $25.91M | 23.10% |
| 2016-06-30 | $25.58M | $89.90M | (m) | $3.21M | $24.39M | 28.45% |
| 2016-03-31 | $28.80M | $78.08M | (m) | $3.44M | $22.31M | 36.88% |
| 2015-12-31 | $32.70M | $76.32M | (m) | $2.87M | $21.16M | 42.84% |
| 2015-09-30 | $37.20M | $79.32M | (m) | $2.78M | $20.44M | 46.90% |
| 2015-06-30 | $36.95M | $76.74M | (m) | $2.85M | $19.10M | 48.15% |
| 2015-03-31 | $26.08M | $63.87M | (m) | $2.71M | $18.98M | 40.83% |
| 2014-12-31 | $20.01M | $55.97M | (m) | $2.68M | $17.93M | 35.74% |
| 2014-09-30 | $12.69M | $45.47M | (m) | $2.63M | $16.62M | 27.92% |
| 2014-06-30 | $5.30M | $35.91M | (m) | $2.21M | $16.04M | 14.77% |
| 2014-03-31 | $3.99M | $35.42M | (m) | $1.79M | $17.78M | 11.27% |
| 2013-12-31 | $898.00K | $30.08M | (m) | $1.71M | $16.39M | 2.99% |
| 2013-09-30 | (m) | $6.80M | (m) | $17.44M | (m) | (m) |
| 2013-06-30 | (m) | $4.00M | (m) | $17.13M | (m) | (m) |
| 2013-03-31 | (m) | $2.33M | (m) | $12.68M | (m) | (m) |
| 2012-12-31 | $-23.17M | $2.30M | (m) | $16.89M | (m) | -1007.14% |
| 2012-09-30 | (m) | $447.54K | (m) | $21.16M | (m) | (m) |
| 2012-06-30 | (m) | $519.94K | (m) | $28.78M | (m) | (m) |
| 2012-03-31 | (m) | $492.16K | (m) | $34.50M | (m) | (m) |
| 2011-12-31 | (m) | $435.16K | (m) | $44.18M | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $2.47M | (m) | $39.71M | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | $1.26M | (m) | $13.68M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |